Abstract

Objective: To explore the roles of anti-mullerian hormone (AMH) and follicle stimulating hormone (FSH) in predicting clinical pregnancy. Materials and Methods: Forty patients who were decided on IVF/ICSI due to different infertility etiologies were included in the study. The patients were divided into two groups according to their AMH and FSH values as having a good prognosis or a poor prognosis. The clinical pregnancy and miscarriage rates of 33 cycles with good prognosis and 17 cycles with poor prognosis were compared. Results: In the good prognosis group, the FSH value was significantly lower than the poor prognosis group (5.98±1.04 mIU/mL vs. 13.6±3.07 mIU/mL, p<0.01), while the serum AMH level was significantly higher. (3.80±1.32 ng/mL vs 0.54±0.02 ng/mL, p<0.01). The rate of chemical pregnancy in the group with good prognosis was twice as high and significant compared to the group with poor prognosis (12 (36.3%) vs 5 (29.4%), p<0.02). In terms of clinical pregnancy rates, the group with good prognosis showed a higher frequency (33.3% vs. 23.5%, p<0.001), while miscarraige rates were higher in the group with poor prognosis (9.0% vs. 25%, p<0.003). Conclusions: Evaluation of AMH and FSH together is critical in determining clinical pregnancy rates.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call